Days after buyout news, Vifor outlines plan to offload 'non-core' finished drug manufacturing wing

Australian firm CSL paid a steep price earlier this week for Vifor Pharma and its pipeline of iron and kidney drugs. Looking to ensure it starts its next phase as battle-ready as possible, Vifor will now dump its “non-core” manufacturing business as it slims down before the merge.